View in EDS PDF Full Text

Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma.

Saved in:
Bibliographic Details
Title: Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma.
Authors: Shaikh SS; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, United States.; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center Hillman Cancer Centet, Pittsburgh, PA, United States., Zang Y; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center Hillman Cancer Centet, Pittsburgh, PA, United States., Hanmer J; Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, United States., Wang H; University of Pittsburgh, School of Public Health, Pittsburgh, PA, United States., Lin Y; University of Pittsburgh, School of Public Health, Pittsburgh, PA, United States., Davar D; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center Hillman Cancer Centet, Pittsburgh, PA, United States., Zarour HM; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center Hillman Cancer Centet, Pittsburgh, PA, United States., Kirkwood JM; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center Hillman Cancer Centet, Pittsburgh, PA, United States., Najjar YG; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center Hillman Cancer Centet, Pittsburgh, PA, United States.
Source: Frontiers in oncology [Front Oncol] 2022 Nov 23; Vol. 12, pp. 1022496. Date of Electronic Publication: 2022 Nov 23 (Print Publication: 2022).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36505793
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Shaikh+SS%22">Shaikh SS</searchLink>; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, United States.; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center Hillman Cancer Centet, Pittsburgh, PA, United States.<br /><searchLink fieldCode="AU" term="%22Zang+Y%22">Zang Y</searchLink>; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center Hillman Cancer Centet, Pittsburgh, PA, United States.<br /><searchLink fieldCode="AU" term="%22Hanmer+J%22">Hanmer J</searchLink>; Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, United States.<br /><searchLink fieldCode="AU" term="%22Wang+H%22">Wang H</searchLink>; University of Pittsburgh, School of Public Health, Pittsburgh, PA, United States.<br /><searchLink fieldCode="AU" term="%22Lin+Y%22">Lin Y</searchLink>; University of Pittsburgh, School of Public Health, Pittsburgh, PA, United States.<br /><searchLink fieldCode="AU" term="%22Davar+D%22">Davar D</searchLink>; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center Hillman Cancer Centet, Pittsburgh, PA, United States.<br /><searchLink fieldCode="AU" term="%22Zarour+HM%22">Zarour HM</searchLink>; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center Hillman Cancer Centet, Pittsburgh, PA, United States.<br /><searchLink fieldCode="AU" term="%22Kirkwood+JM%22">Kirkwood JM</searchLink>; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center Hillman Cancer Centet, Pittsburgh, PA, United States.<br /><searchLink fieldCode="AU" term="%22Najjar+YG%22">Najjar YG</searchLink>; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center Hillman Cancer Centet, Pittsburgh, PA, United States.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101568867%22">Frontiers in oncology</searchLink> [Front Oncol] 2022 Nov 23; Vol. 12, pp. 1022496. <i>Date of Electronic Publication: </i>2022 Nov 23 (<i>Print Publication: </i>2022).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101568867 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2234-943X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222234943X%22">2234943X </searchLink><i>NLM ISO Abbreviation: </i>Front Oncol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36505793
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fonc.2022.1022496
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1022496
    Titles:
      – TitleFull: Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Shaikh SS
      – PersonEntity:
          Name:
            NameFull: Zang Y
      – PersonEntity:
          Name:
            NameFull: Hanmer J
      – PersonEntity:
          Name:
            NameFull: Wang H
      – PersonEntity:
          Name:
            NameFull: Lin Y
      – PersonEntity:
          Name:
            NameFull: Davar D
      – PersonEntity:
          Name:
            NameFull: Zarour HM
      – PersonEntity:
          Name:
            NameFull: Kirkwood JM
      – PersonEntity:
          Name:
            NameFull: Najjar YG
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 23
              M: 11
              Text: 2022 Nov 23
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-print
              Value: 2234-943X
          Numbering:
            – Type: volume
              Value: 12
          Titles:
            – TitleFull: Frontiers in oncology
              Type: main
ResultId 1